The effects of new pharmaceutical composition containing Epigallocatechin-3-Gallate (EGCG) to inhibit methylation of the tumor supressor genes in patients with cervical intraepithelial neoplasia

Cover Page

Abstract


Purpose: to develop preventive measures and reasonable therapy of pathological processes in the cervix uteri based on detection of methylation of tumor suppressor genes and groups at high-risk of cancer among patients of reproductive age with benign and premalignant cervical processes. Effectiveness of complex pathogenetic treatment of the cervix uteri has been evaluated in 127 women of reproductive age with benign and premalignant cervical processes before and after the combined treatment with a pharmaceutical composition containing active substance epigallocatechin-3-gallate (EGCG). Shown that pharmaceutical composition containing EGCG contributes demethylation of the tumor suppressor genes that confirm powerful oncoprotector action in treating precancerous lesions. One year after the complex combined therapy (including surgery) with pharmaceutical composition containing EGCG, recurrent cervical pathological processes have not been detected in patients with benign lesions, CIN I and CIN II.

I S Sidorova

I.M. Sechenov First Moscow State Medical University (1st MSMU)

Email: druhvm@gmail.com

A L Unanyan

I.M. Sechenov First Moscow State Medical University (1st MSMU)

Email: druhvm@gmail.com

V M Drukh

Peoples’ Friendship University of Russia

Email: druhvm@gmail.com

E L Muyzhnek

ZAO «MiraxBioPharma»

Email: MuyzhnekEL@ilmixgroup.ru

Views

Abstract - 67

PDF (Russian) - 39


Copyright (c) 2014 Сидорова И.С., Унанян А.Л., Друх В.М., Муйжнек Е.Л.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.